In Vitro Bedaquiline and Clofazimine Susceptibility Testing in Mycobacterium abscessus

Schulthess B., Kittana F. N., Hömke R., Sander P.

Antimicrobial Agents and Chemotherapy, vol.66, no.5, 2022 (SCI-Expanded, Scopus) identifier identifier

  • Publication Type: Article / Article
  • Volume: 66 Issue: 5
  • Publication Date: 2022
  • Doi Number: 10.1128/aac.02346-21
  • Journal Name: Antimicrobial Agents and Chemotherapy
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, Chimica, EMBASE, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database, DIALNET
  • Keywords: antibiotic susceptibility testing, bedaquiline, clofazimine, ECOFF, epidemiological cutoff, MIC, Mycobacterium abscessus
  • Uşak University Affiliated: No

Abstract

Bedaquiline and clofazimine are increasingly used to treat infections with Mycobacterium abscessus. We determined distributions of MICs by broth microdilution for bedaquiline and clofazimine for 61 M. abscessus clinical isolates using different media and incubation times. We show that incubation time and growth media critically influence the MIC. Our data will aid in defining future clinical breakpoints for in vitro susceptibility testing for bedaquiline and clofazimine in M. abscessus.